Friday, AbbVie Inc ABBV reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23.
Net revenues reached $12.31 billion, up 0.7%, beating the consensus of $11.92 billion. Sales were up 1.6% on an operational basis.
“First quarter results were well ahead of our expectations, driven by excellent performance from our ex-Humira growth platform,” said Robert Michael, president and chief operating officer.
The immunology portfolio generated $5.37 billion in sales, down 3.9% on a reported basis or 3.1% on an operational basis, due to Humira biosimilar competition.
Humira revenues were $2.27 billion (down 35.9%), Skyrizi sales reached $2.01 billion (up 47.6%), and Rinvoq revenues were $1.09 billion (up 59.3%).
Related: AbbVie’s Dermatitis Drug Shown ‘Superior’ To Sanofi/Regeneron’s Dupixent In Head-To-Head Study.
Last month, AbbVie agreed to acquire Landos Biopharma Inc LABP for $20.42 per share, or approximately $137.5 million, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million.
Oncology product sales were $1.54 billion, up 9% or 9.8% on an operational basis.
Imbruvica revenues were $838 million (down 4.5%), Venclexta sales increased 14.2% to $614 million, and Elahere net revenues were $64 million, reflecting a partial quarter of sales based on February 12, 2024, close date of the ImmunoGen acquisition.
Neuroscience revenues reached $1.97 billion, up 15.9% on a reported basis or 16% on an operational basis.
Botox Therapeutic sales were $748 million, up 4.1%. Aesthetics portfolio sales reached $1.25 billion, down 4%. Global Botox Cosmetic revenues were $633 million, down 3.9%.
Guidance: AbbVie raised its 2024 adjusted EPS guidance from $10.97-$11.17 to $11.13-$11.33, which includes an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense incurred during the first quarter of 2024, versus consensus of $11.12.
Price Action: ABBV shares are down 3.41% at $161.58 at the last check Friday.
Photo via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
